Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

Obesity pipeline

How much weight loss, trial by trial.

Each card is one trial arm against its own placebo, at the weeks the source reports. The default card is the highest stated milligram dose.

5 cards with an efficacy estimand. 22 cards have a weight figure and no stated estimand.

GLP-1 RA 1

Semaglutide

Dose n/r · Efficacy

Obesity or overweight

Y axis: Change in body weight from baseline, %

1050-5-1004812162024Placebo, week 20, 6.5%PlaceboSemaglutide, week 20, -8.3%Semaglutide

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-8.3% at week 20

STEP 4 · NCT03548987

Amylin 4

Eloralintide

1 mg · Efficacy

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10048121620243648Placebo, week 48, -0.4%Placebo1 mg Eloralintide, week 48, -9%1 mg Eloralintide

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-9% at week 48

Study · NCT06230523

Eloralintide

3 mg · Efficacy

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10-15048121620243648Placebo, week 48, -0.4%Placebo3 mg Eloralintide, week 48, -12%3 mg Eloralintide

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-12% at week 48

Study · NCT06230523

Eloralintide

6 mg · Efficacy

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10-15-20048121620243648Placebo, week 48, -0.4%Placebo6 mg Eloralintide, week 48, -18%6 mg Eloralintide

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-18% at week 48

Study · NCT06230523

Eloralintide

9 mg · Efficacy

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10-15-20048121620243648Placebo, week 48, -0.4%Placebo9 mg Eloralintide, week 48, -20%9 mg Eloralintide

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-20% at week 48

Study · NCT06230523

Estimand not reported 22

These arms report a weight change and do not name ITT or efficacy. They stay out of both estimand sets.

Cagrilintide/semaglutide

cagrilintide 2.4 mg and semaglutide 2.4 mg · n/r

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10-15-20-250481216202436486072Placebo, week 68, -3%PlaceboCagrisema, week 68, -20.4%Cagrisema

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-20.4% at week 68

REDEFINE 1 · NCT05567796

VK2735

2.5 mg · n/r

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-1004812162024Placebo, week 13, -1.7%PlaceboVK2735 2.5 mg, week 13, -9.1%VK2735 2.5 mg

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-9.1% at week 13

VENTURE · NCT06068946

VK2735

15 mg · n/r

Obesity, no T2D

Y axis: Change in body weight from baseline, %

0-5-10-1504812162024Placebo, week 13, -1.7%PlaceboVK2735 15 mg, week 13, -14.7%VK2735 15 mg

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-14.7% at week 13

VENTURE · NCT06068946

Exenatide

Dose n/r · n/r

Obesity or overweight

Y axis: Change in body weight from baseline, %

500481216202436Placebo, week 36, 3.5%PlaceboExenatide once weekly extended-release, week 36, 1.7%Exenatide once weekly extended-release

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

1.7% at week 36

ECHO · NCT02664441

Liraglutide

3.0mg · n/r

Obesity or overweight

Y axis: Change in body weight from baseline, %

5004812162024364860Placebo, week 56, 0.28%PlaceboLiraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68), week 56, 0.69%Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

0.69% at week 56

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes · NCT01272219

Liraglutide

3.0mg · n/r

Obesity or overweight

Y axis: Change in body weight from baseline, %

5004812162024364860Placebo, week 56, 0.28%PlaceboLiraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), week 56, 2.91%Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

2.91% at week 56

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes · NCT01272219

Liraglutide

Dose n/r · n/r

Obesity + T2D

Y axis: Change in body weight from baseline, %

10500481216202436Placebo, week 32, 1.4%PlaceboLiraglutide Pen Injector (Saxenda), week 32, 5.7%Liraglutide Pen Injector (Saxenda)

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

5.7% at week 32

SAXAPCOS · NCT03480022

Setmelanotide

Dose n/r · n/r

Bardet Biedl Syndrome (BBS); Alström Syndrome...

Y axis: Change in body weight from baseline, %

0-5-1004812162024364860Pivotal Cohort, week 52, -5.21%Pivotal Cohort

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

One reported week is a point. It is not a line from 0%.

-5.21% at week 52

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity · NCT03746522

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.